{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Overall incidence and severity of Adverse Events in Number of Participants with Adverse Events in Dose Escalation","groups":[{"description":"(1) Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG000","title":"Arm A - Dose Level 1"},{"description":"(2) Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG001","title":"Arm A - Dose Level 2"},{"description":"(1) Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG002","title":"Arm B - Dose Level 1"},{"description":"(2) Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG003","title":"Arm B - Dose Level 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"3 patients were enrolled in Arm A, Dose Level 1. Arm A was closed due to AEs and no patients enrolled in Arm A, Dose Level 2 3 patients were enrolled in Arm B, Dose Level 1. Then 4 new patients were enrolled in Arm B, Dose Level 2.\n\nPart 2 was stopped with the FDA withdrawal of the drug approval and reluctance of patients to participate.","reportingStatus":"POSTED","timeFrame":"Up to 6 weeks","title":"Number of Participants With Adverse Events in Dose Escalation","type":"PRIMARY","unitOfMeasure":"Participants"}